Novel Purification and Testing of the Antimicrobial Agent Moenomycin A Using Starbon® A300 and Enhancement of in vivo Efficacy with n-dodecyl-β-D-maltoside.

Antibiotic resistance is a growing global health crisis. This project aims to develop a new purification and delivery method for Moenomycin A, a novel antibiotic. The single-step purification method includes culturing Streptomyces viridosporus DSM 40746 on TSB media, purifying the extract and spent culture media utilising Starbon® A300 and measuring the purified extracts antimicrobial activity by quantifying its inhibitory effects on the growth of a Bacillus subtilis lawn. This project also addresses Moenomycin A’s unfavourable binding with blood plasma proteins, a major limitation of Moenomycin A for clinical use. n-dodecyl-β-D-maltoside (DDM) and PEG400 were investigated to mitigate this binding in order to decrease Moenomycin A’s minimum inhibitory concentration (MIC).